ONA Therapeutics
Dr. Mark Throsby is a biopharmaceutical executive with extensive research experience and a track record of innovation and execution. He gained a PhD in Immunology from Monash University Melbourne, Australia and spent four years as a research fellow with CNRS in Paris. Dr Throsby started his industry career at Crucell NV and worked there for 8 years in various roles, notably as Director of Antibody discovery. Dr Throsby joined Merus BV in 2008 as COO (CSO from 2013) leading all the research activities of the company. He is an expert in antibody engineering and immunology with more than a dozen granted patents and >40 peer reviewed publications.
This person is not in the org chart
This person is not in any offices
ONA Therapeutics
Ona Therapeutics is a biotech company, spin-off of ICREA and IRB, specialized in the discovery and development of therapeutic biologics targeting tumor metastatic-initiating cells and lipid metabolism.